Sage Journals: Discover world-class research

Abstract

Introduction

The excision repair cross-complementation group 2 (ERCC2) ATP-dependent helicase is an essential member of the DNA repair pathway. It has been observed to be differentially expressed in different cancers, which shows its involvement in carcinogenesis.

Aim

In the present study we have tried to determine the association of expression patterns of this gene with head and neck carcinogenesis.

Method

We first carried out a systematic review of the available studies on the role of ERCC2 in head and neck cancer (HNC). In order to test the hypothesis that the expression patterns of XPD/ERCC2 play a critical role in HNC pathogenesis, we then conducted a population based case-control study on 81 head and neck tumor samples and adjacent normal-tissue control samples. Reverse transcriptase polymerase chain reaction (RT-PCR) and quantitative polymerase chain reaction (qPCR) were used to assess ERCC2 deregulation at the mRNA level.

Result

Expression analysis showed that the ERCC2 expression level was significantly upregulated (p<0.05) in HNC tissues compared with adjacent normal tissues. Furthermore, the expression pattern of ERCC2 was correlated with the expression pattern of Ki-67 and a significant correlation (r = 0.230, p<0.03) was observed between ERCC2 and Ki-67. Spearman's correlation also showed a significant correlation between ERCC2 expression and tumor stage (r = 0.271, p<0.02) and grade (r = 0.228, p<0.02) of HNC.

Conclusions

Our data suggest that deregulation of ERCC2 in HNC has the potential to predict a more aggressive cancer phenotype and may be considered a possible biomarker for improved diagnosis and prognosis of HNC.

Keywords

HNC Ki-67 Proliferation marker Tumor size XPD/ERCC2

Introduction

Head and neck cancer (HNC) is the sixth most common type of cancer across the world. Approximately more than 600,000 new patients are diagnosed and 350,000 individuals die of this disease worldwide each year (1). It has been identified as a common malignancy in the Pakistani population, accounting for 21% of cancers in men and 11% in women (2, 3). The main risk factors for HNC include tobacco use, alcohol consumption, ionizing radiation, reactive oxygen species, occupational exposure, HPV infection, and genetic susceptibility (4-5-6-7-8-9-10-11-12-13). Since DNA is frequently damaged by these different endogenous and exogenous carcinogens, this genomic instability plays a pivotal role in the development of HNC (14). The damage is routinely removed by different repair pathways, among which the nucleotide excision repair pathway (NER) is an important DNA repair pathway that removes DNA adducts induced by mutagens and carcinogens in a number of sequential steps (15, 16).

The excision repair cross-complementation group 2 (ERCC2) gene, also called xeroderma pigmentosum group D (XPD), is located on chromosome 19q13.3 and comprises 23 exons; it is one of the main components of the NER pathway (17). It is an ATP-dependent helicase and an essential part of the transcription repair factor complex TFIIH (18). This gene encodes a protein which contributes to 3 critical cellular mechanisms: (i) repair of damaged DNA in the NER pathway, (ii) general transcription, and (iii) cell cycle regulation through its interaction with cyclin-activating kinase (CAK), which is a key activator of cyclin-dependent kinases (19). In the NER pathway, ERCC2 removes some DNA cross-links, UV lesions, bulky chemical adducts, and thymidine dimers (20). The helicase activity of ERCC2 unwinds DNA around the damaged site in the 5’-3’ direction so as to allow the damage-specific nucleases to cleave the DNA on both sides of the damage (21).

Genetic variations in DNA repair genes such as ERCC2 affect the DNA repair capacity. Polymorphisms of the ERCC2 gene are thought to be associated with a high risk of various cancer types such as colorectal cancer, gastric adenocarcinoma, lung carcinoma, urinary bladder carcinoma, skin melanoma, breast cancer and HNC (22). ERCC2 polymorphisms may lead to reduced helicase activity and ultimately DNA repair capacity, which can be important in the carcinogenesis and development of HNC (23). Three polymorphisms of ERCC2 have been extensively studied worldwide. These include C→A, leading to Arg156Arg in exon 6, G→A, leading to Asp312Asn in exon 10, and A→C, leading to Lys751Gln in exon 23 (24).

With regard to expression deregulation of the ERCC2 gene, a limited number of studies on the role of its expression in different cancers are available. We have therefore performed quantitative reverse-transcriptase PCR to determine the relative expression levels of ERCC2. Furthermore, we have correlated the expression of ERCC2 with the expression of the proliferation marker Ki-67.

Materials and methods

Publication Search

To identify the relevant literature, a PubMed search was performed for ERCC2 studies that used human blood and tissue samples obtained from HNC patients along with corresponding control and noncancerous tissues. The following criteria were adopted for the inclusion of studies in this systematic review:

(i)

studies on mutation screening and expression analysis of ERCC2 in patients with HNC

(ii)

studies using blood samples, HNC tumor samples, control blood samples and adjacent noncancerous tissues, respectively, for comparison

(iii)

studies performed with mutation detection and expression analysis techniques

(iv)

studies published as full articles in English

Studies using cancer cell lines, serum or saliva samples were not included. Review articles and meta-analyses were also excluded from the present study.

Tumor Sample Collection

Surgical sections of head and neck squamous cell carcinoma (HNSCC) along with adjacent normal tissues (from a microscopically confirmed uninvolved area more than 2 cm away from the tumor section) were collected from 81 HNSCC patients immediately after surgery at the Pakistan Institute of Medical Sciences, Islamabad. Inclusion criteria for patients were: (i) histologically confirmed HNSCC; (ii) no previous chemotherapy, radiotherapy or surgery for the tumor; (iii) no previous history of cancer; and (iv) planned surgical treatment. Tumor and control tissues were stored in RNA at -80°C. Frozen sections of collected tumor and control tissues were analyzed for the presence of tumor cells by a consultant pathologist using hematoxylin and eosin staining. A specifically designed consent form was completed for each patient and signed by the patient. Information about addiction, ethnic group, gender and age was recorded. The study was approved by the ethics committees of the COMSATS Institute of Information Technology and the Pakistan Institute of Medical Sciences. Clinical or pathological staging and identification of the lesions were based on the International Union Against Cancer TNM Classification of Malignant Tumors of 2003.

RNA Extraction and cDNA Synthesis

RNA was isolated from HNC tumor samples and control samples using the standard Trizol reagent method (25). Extracted RNA was analyzed on 1% TAE gel to confirm the isolation of RNA. After isolation, the RNA yield was quantified with a UV spectrophotometer. Absorbance was measured at wavelengths of 260 and 280 nm. Extracted RNA was stored at -80°C. cDNA was synthesized with the SuperScript III First-Strand Synthesis System (Invitrogen). Single-stranded cDNA was synthesized from purified total RNA and stored at 4°C.

Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)

RT-PCR was used to analyze RNA expression. RT-PCR was carried out to assess the expression variations of the ERCC2 gene in HNC tumor samples. The reaction conditions optimized for this reaction were as follows: initial denaturation for 2 minutes at 95°C and 35 cycles of 94°C for 15 seconds, annealing at 56°C for 15 seconds and 72°C for 30 seconds, and final extension at 72°C for 10 minutes. β-actin was amplified as internal control to check the specificity of the reaction. Amplified products were either stored at 4°C or electrophoresed on a 2% agarose gel after completion of the PCR reaction. Their densities were analyzed using the Quantity One software (Bio-Rad Laboratories).

Quantitative Polymerase Chain Reaction (qPCR)

For qPCR, primers specific for ERCC2, Ki-67 and the reference gene β-actin were obtained from IDT DNA Technology. Each qPCR was performed in a 10-µL reaction mixture containing 1 µL cDNA, 1 µL of each forward and reverse primer, 5 µL SYBR Green Master Mix, and 2 µL RNase-free water. qPCR was performed using the StepOnePlus PCR system (Applied Biosystems) at 56°C under standard conditions. The relative mRNA expression of ERCC2 and Ki-67 was computed using the 2^{-delta delta Ct} analysis method with β-actin as the reference gene.

Statistical Analysis

One-way ANOVA, Tukey's post hoc test, Bartlett's test and Student's t-test were used to assess the association of ERCC2 and Ki-67 expression with clinical and histopathological parameters (e.g., TNM stage and grade). Spearman's correlation coefficient was used to assess correlations among gene-gene expression and gene-clinical and histopathological parameters. Statistical analysis was performed using the GraphPad Prism 5 software and SPSS software package.

Results

Study Characteristics

A total of 197 potentially relevant studies were retrieved after a comprehensive search of the PubMed database (Fig. 1), and 124 of these studies were excluded for being not relevant to HNC or ERCC2. A further 45 studies including 18 meta-analyses, 5 reviews, 10 studies carried out on cell lines, 4 studies with no control data, 6 studies with missing data, and 2 studies in languages other than English were excluded. Consequently, 26 studies on the association of ERCC2 polymorphisms with the risk of HNC and only 2 studies on expression analysis of the gene in HNC were included in the systematic review, as shown in Figure 1.

Fig. 1

Flowchart of the process used for selection of eligible studies.

The characteristics of the 28 eligible studies, including year of publication, ethnicity of studied population, type of cancer, method of genotyping, and sample size for ERCC2 are listed in Table I. All studies were published between 2000 and 2014.

Table I

Literature search in PubMed database for eligible studies reporting on the ERCC2 gene in head and neck carcinoma

Previous studies of mutational analysis
Study	Year	Population	Cancer	Sample size		Technique
				Patients	Controls
Sturgis et al (37)	2000	Caucasian	HNC	189	496	PCR-RFLP
Sturgis et al (38)	2002	Non-Hispanic	Squamous cell HNC	330	330	PCR-RFLP
Rydzanicz et al (39)	2005	Caucasian	HNC	182	143	PCR-RFLP
Huang et al (40)	2005	Caucasian	HNC	555	792	Taqman
Kietthubthew et al (41)	2006	Asian	OSCC	106	164	PCR-RFLP
Ramachandran et al (42)	2006	Asian	Oral cancer	110	110	PCR-RFLP
Matullo et al (43)	2006	Caucasian	HNC	88	1094	Taqman
Bau et al (44)	2007	Asian	Oral cancer	154	105	PCR-RFLP
Wang et al (45)	2007	Mix	Oral cancer	144	288	PCR-RFLP
Yang et al (46)	2007	Asian	Nasopharynx	153	168	PCR-RFLP
Majumder et al (47)	2007	Asian	Oral cancer	310	389	PCR-RFLP
An et al (48)	2007	Non-Hispanic	HNC	829	854	PCR-RFLP
Harth et al (49)	2008	Caucasian	HNC	312	300	PCR-RFLP
Mitra et al (50)	2009	Caucasian	HNC	285	400	PCR-RFLP
Abbasi et al (51)	2009	Caucasian	Laryngeal cancer	248	647	PCR-RFLP, RT-qPCR
Jelonek et al (52)	2010	Caucasian	HNC	105	507	PCR-RFLP
Ji et al (53)	2010	Asian	HNC	290	358	PCR
Mahimkar et al (54)	2010	Asian	Leukoplakia	66	101	PCR-RFLP
Gugatschka et al (55)	2011	Caucasian	HNC	169	463	Taqman
Sliwinski et al (56)	2011	Caucasian	HNC	265	280	PCR-RFLP
Kumar et al (57)	2012	Asian	HNC	278	278	PCR-RFLP
Yuan et al (58)	2012	Asian	HNC	397	900	Taqman
Kostrzewska-Poczekaj et al (59)	2013	Caucasian	HNC	205	160	PCR-RFLP
Lu et al (60)	2014	Asian	Laryngeal cancer	197	197	Sequenom MassARRAY
Visuvanathan et al (19)	2014	Asian	Nasopharynx	157	136	PCR-RFLP
Khlifi et al (22)	2014	African	HNC	169	261	PCR-RFLP
Previous studies of expression analysis
Cheng et al (61)	2002	Mixed	HNC	57	105	RT-qPCR
Kumar et al (29)	2012	Asian	HNC	75	75	RT-qPCR

HNC = head and neck cancer; OSCC = oral squamous cell carcinoma; PCR = polymerase chain reaction; RFLP = restriction fragment length polymorphism; RT-qPCR = quantitative reverse transcriptase polymerase chain reaction.

Expression of ERCC2 measured by RT-PCR

In the present study cohort, the expression profiles of ERCC2 were analyzed using RT-PCR in 81 HNC samples and compared with adjacent noncancerous tissues. The demographic characteristics of the study cohort are summarized in Table II. In most tumor tissue samples, ERCC2 expression was upregulated (p<0.04) compared with noncancerous tissues (Fig. 2). β-actin expression was used as internal control in this experiment to show that an equal amount of cDNA was used in all samples (Fig. 2). Uniform expression of β-actin indicates an equal concentration of RNA and valid RT-PCR.

Table II

Demographic and clinical parameters of the study cohort

Variables	Cancer patients N (%)	Healthy controls N (%)^†
Age
Mean	52 ± 0.5	52 ± 0.5
<40 n (%)	17 (21)	17 (21)
>40 n (%)	64 (79)	64 (79)
Gender
Male n (%)	43 (53)	43 (53)
Female n (%)	38 (47)	38 (47)
Cancer site
Oral cavity n (%)	20 (25)
Pharynx n (%)	18 (22)
Larynx n (%)	43 (53)
Clinical stage
I-II n (%)	34 (42)
III-IV n (%)	47 (58)
TNM stage
T stage
T1-T2 n (%)	34 (42)
T3-T4 n (%)	47 (58)
N stage
N0 n (%)	33 (41)
N1-N2 n (%)	48 (59)
M stage
M0 n (%)	78 (96)
M1 n (%)	3 (4)
Survival data
Cured n (%)	26 (32)
Under treatment n (%)	31 (38)
Deceased n (%)	24 (30)
Grade
Poorly differentiated n (%)	19 (23)
Moderately differentiated n (%)	24 (30)
Well differentiated n (%)	38 (47)

†

Adjacent uninvolved healthy tumor section taken as control.

Fig. 2

Expression pattern of ERCC2 gene in tumor tissue samples. ERCC2 expression in HNC tumor tissues (A). ERCC2 expression in adjacent control tissues (B). β-actin expression in HNC tumor tissues (C). Relative mRNA levels of ERCC2 in tumor and control tissue samples after analysis with Quantity One software (D).

Expression of XPD/ERCC2 measured by qPCR

In order to further confirm the expression patterns of the ERCC2 gene in the same study cohort, qPCR was used. Significant upregulation of ERCC2 was observed in HNC tumor tissues compared with adjacent noncancerous tissue samples (Fig. 3). A statistically significant increase in ERCC2 mRNA levels was observed in larger tumors (T3-T4) compared with smaller tumors (T1-T2). With regard to other parameters, increased expression of ERCC2 was observed in tumors with more advanced clinical stage, lymph node involvement and metastases compared with early-stage tumors, but this increase was not statistically significant (Fig. 3). Significantly increased ERCC2 expression was observed in poorly to moderately differentiated tumors compared with well differentiated tumors. Moreover, significant upregulation was observed in HNC patients still receiving cancer treatment (chemotherapy and radiotherapy) compared to cured and deceased HNC patients. With regard to tumor site, significantly increased ERCC2 mRNA levels were observed in patients with oral carcinoma compared to patients with laryngeal carcinoma and pharyngeal carcinoma (Fig. 4).

Fig. 3

mRNA expression of ERCC2 in HNC tumor samples. Column plot comparing the ERCC2 mRNA levels of HNC tumor and normal control samples, HNC tumor samples at clinical stage I-II and clinical stage III-IV, HNC tumor samples at different pT stages, HNC tumor samples with lymph node involvement (N1-N2) and without lymph node involvement (N0), and HNC tumor samples with metastasis (M1) and without metastasis (M0) *p<0.05.

Fig. 4

mRNA expression of ERCC2 in HNC tumor samples. Column plot comparing the ERCC2 mRNA levels of HNC tumor samples in different areas, in different grades of HNC tumors, and with survival data. The p values were computed using one-way ANOVA, Tukey's post hoc test and chi-square test

Expression of Ki-67 measured by qPCR

Expression analysis of the proliferation marker Ki-67 was also carried out by qPCR in 81 HNC tissues and compared with adjacent uninvolved normal tissue used as control. Highly significant (p<0.008) upregulation of the Ki-67 gene was observed in tumor tissues compared with adjacent normal tissues (Fig. 5). Upregulated expression of Ki-67 was observed in advanced clinical stage (III-IV), tumor stage (T3-T4), lymph node status (N1-N2) and metastatic stage (M1-M2) and in poorly differentiated tumors, but this upregulation was statistically nonsignificant (Fig. 5). Highly significant (p<0.006) upregulation of Ki-67 was observed in deceased patients compared with cured patients and those still under treatment for HNC (Fig. 6). Relative expression of the Ki-67 gene was compared in different areas of the head and neck using ANOVA. Significant upregulation (p<0.001) was observed tumors of the oral cavity and pharynx compared with tumors of the larynx (Fig. 6).

Fig. 5

mRNA expression of Ki-67 in HNC tumor samples. Column plot comparing the Ki-67 mRNA levels of HNC tumor and normal control samples, HNC tumor samples at clinical stage I-II and clinical stage III-IV, at different pT stages, with lymph node involvement (N1-N2) and without lymph node involvement (N0), and with metastasis (M1) and without metastasis (M0) *p<0.05; **p<0.01.

Fig. 6

mRNA expression of Ki-67 in HNC tumor samples. Column plot comparing the Ki-67 mRNA levels of HNC tumor samples in different areas, with different grades of HNC tumor samples, and with survival data. The p values were computed using one-way ANOVA, Tukey's post hoc test and chi-square test *p<0.05; **p<0.01.

Correlations between different Clinicopathological Characteristics

With regard to the relationship between different clinicopathological characteristics, a positive correlation was observed between gender versus area (r = 0.312**, p<0.005), pT versus pC (r = 0.930**, p<0.001), pT versus pN (r = 0.990**, p<0.001), pT versus grade (r = 0.231*, p<0.03), pC versus pN (r = 0.920**, p<0.001), and pC versus grade (r = 0.227*, p<0.04). A negative correlation was observed between age versus pT (r = -0.342**, p<0.002), age versus pC (r = -0.323**, p<0.003), age versus pN (r = -0.317**, p<0.004), and age versus area (r = -0.307**, p<0.005) (Tab. III).

Table III

Correlations between NER pathway gene (ERCC2), proliferation marker (Ki-67) expression and clinicopathological characteristics of primary HNC^†

Gender	Age	pT	pC	pN	pM	Grade	Area	Survival	ERCC2	Ki-67
Gender	-0.179	0.036	0.163	0.048	0.087	0.018	0.312^**	0.060	0.148	0.011
Age		-0.342^**	-0.323^**	-0.317^**	-0.26	-0.216	-0.307^**	-0.203	-0.011	-0.167
pT			0.930^**	0.990^**	-0.042	0.231^*	0.129	-0.004	0.271^*	0.149
pC				0.920^**	-0.017	0.227^*	0.159	0.067	0.038	0.112
pN					-0.060	0.200	0.119	-0.001	0.030	0.120
pM						0.163	-0.045	0.021	0.132	-0.071
Grade							0.028	0.111	0.228^*	-0.023
Area								0.189	0.035	0.071
Survival									-0.149	0.103
ERCC2										0.230^*
Ki-67

NER = nucleotide excision repair; HNC = head and neck cancer; pT = T-stage for primary tumor; pC = clinical stage for primary tumor; pN = lymph node stage for primary tumor; pM = metastasis stage for primary tumor.

†

Spearman's correlation coefficients. The expression levels of ERCC2 and Ki-67 for the patient cohort were based on the relative mRNA level.

p<0.05; The p values were computed using one-way ANOVA and χ2 test.

p<0.01.

With regard to correlations between histopathological parameters and gene expression, a positive correlation was observed between pT versus ERCC2 (r = 0.271*, p<0.02) and grade versus ERCC2 (r = 0.228*, p<0.02). In case of gene-gene interaction, a positive correlation was observed between ERCC2 and Ki-67 (r = 0.230*, p<0.03) (Tab. III).

From this correlation study it is important to note that in HNC patient groups positive correlations were consistently observed between ERCC2 expression, T stage and tumor grade. As illustrated in Table IV, statistical analysis revealed that the ERCC2 expression level in HNC patients was associated with T stage and tumor grade (p<0.0007 and p<0.0003, respectively).

Table IV

Association of increased ERCC2 expression in HNC with tumor size and grade

	N	Average	ERCC2	Variance
T1-T2^†	34	6.18		4.02
T3-T4^†	47	16.87	(p<0.0007)	3.37
Well^‡	19	7.90		0.2
Mod-Poor^‡	62	15.57	(p<0.0003)	0.95

One-way ANOVA and Tukey's post hoc test were used to assess the association of ERCC2 with tumor size^† and grade^‡.

Well = well differentiated; Mod = moderately differentiated; Poor = poorly differentiated.

Discussion

Genetic variations in different genes involved in repair mechanisms may contribute to an increased incidence of different cancers including HNC. Among these mechanisms, the NER pathway is an important DNA repair pathway which removes DNA adducts induced by mutagens and carcinogens in a number of sequential steps (15, 16). DNA adducts are mainly formed by exposure to UV light, ionizing radiation, drugs and reactive oxygen species (26). The ERCC2 gene is an important member of the NER pathway and helps to remove DNA adducts. In many earlier studies, differential expression of ERCC2 has been reported in various cancer types. However, the results have been inconclusive and further studies are warranted to elucidate the role of ERCC2 expression in carcinogenesis. In this context we conducted a case-control study to analyze the expression patterns of ERCC2 in HNC patients of Pakistani origin.

We first carried out a systematic review, which showed that to date most of the studies (n = 26) on the role of ERCC2 in HNC have focused on mutation profiling of XPD/ERCC2 in HNC and little data is available regarding variations in the expression of ERCC2 in HNC: only 2 studies analyzed ERCC2 expression levels in HNC. We therefore designed a case-ontrol study to (i) evaluate the role of the selected DNA repair pathway gene ERCC2 in HNC tumor tissues, and (ii) further correlate the expression levels of the gene with different histopathological parameters of the study cohort.

In the first step, we analyzed the ERCC2 expression levels in tumor samples of 81 HNC patients along with adjacent normal control tissue samples using RT-PCR. An upregulated level of ERCC2 was observed in HNC tumor tissues compared with adjacent controls tissues. In the second step, we confirmed the results by assessing the ERCC2 expression profiles using qPCR in the same study cohort. Statistically significant upregulation was observed in HNC samples compared with control tissue samples. A similar trend in expression had earlier been observed in 21 HNSCC patients by qPCR analysis (27). However, qPCR-based expression analysis of ERCC2 has also found significant downregulation of the gene in HNSCC (75 cases) and esophageal squamous cell carcinoma (100 cases) compared with the respective controls (28, 29). The difference between the expression patterns of patients and controls suggests genetic heterogeneity in gene expression, which might be the result of different genetic variations, epigenetic characteristics, or environmental factors. Another factor that could generate variations in the expression levels of biomarkers in HNC is that HNC is a complex disease involving different anatomical sites (30). In this study, the ERCC2 gene was found to be upregulated further in more advanced tumor stages and higher tumor grades of HNC. A similar pattern of positive correlation between gene expression and T staging has earlier been observed in other DNA repair genes (APEX1 and OGG1) in HNC patients (31, 32). This study confirmed that deregulation of the DNA repair gene ERCC2 in HNC resulted in higher tumor aggressiveness.

In the third step, we assessed the expression levels of the proliferation marker Ki-67 in our study cohort and observed significant upregulation in HNC tumor tissues compared with adjacent control tissues. A similar pattern of Ki-67 overexpression has been reported in different cancers (33, 34). Jiang et al (35) reported that Ki-67 overexpression is related to increased tumor proliferation, recurrence and metastasis. As regards the association between Ki-67 expression and histopathological parameters in the study cohort, upregulation of Ki-67 was observed in more advanced stages and grades of HNC. Increased Ki-67 expression is indicative of more aggressive tumors (31).

The expression levels of ERCC2 and Ki-67 were correlated using Spearman's correlation coefficient. A significant positive correlation was observed between ERCC2 and Ki-67. In the present study, Ki-67 upregulation combined with deregulation of the DNA repair gene ERCC2 appeared to be linked to excessive proliferation in HNC tumor samples, resulting in more aggressive tumors and consequently an increased level of carcinogenesis. Similar results have been reported in studies where Ki-67 expression was correlated with other genes such as p53 (36), XRCC1 and OGG1 (31), and APEX1 (32).

Based on these results, we can conclude that ERCC2 is overexpressed in HNC tumor tissue compared with adjacent control tissue and that the upregulation is associated with an aggressive disease phenotype. Our data also suggest that deregulation of the DNA repair pathway gene combined with overexpression of the proliferation marker Ki-67 may illuminate the association of the DNA repair pathway with the proliferation pathway.

Although this is not first report in relation to the global context, Pakistani populations have not been analyzed for such genetic variations and their association with different types of cancers. Nevertheless, our sample size (81 tumor tissues and adjacent control tissues) is comparatively small. Further, validation studies with larger sample size and additional stratification to control for potential confounding factors such as smoking status and DNA adduct level are required to validate our findings.

In conclusion, our study has demonstrated a significant association between the ERCC2 expression pattern and HNC at the mRNA level in the Pakistani population. Our study also confirms that ERCC2 expression levels are significantly increased in HNC compared with noncancerous healthy tissues. The ERCC2 expression level is further enhanced in more aggressive HNC tumors. In line with previous findings, inhibition of DNA repair activities of ERCC2 due to expression deregulation or any inhibitors could potentially sensitize the tumor cells to therapeutic agents, making ERCC2 an attractive molecular target in the treatment of cancer.

Footnotes

Acknowledgment

All authors wish to acknowledge the patients who contributed to this research work. We are also thankful to the hospital staff of the Nuclear Oncology and Radiotherapy Institute Islamabad (NORI) and Military Hospital Rawalpindi (MH), Pakistan, for their help and cooperation.

Financial support: None.

Conflict of interest: All authors declare that they have no conflict of interests.

References

Dixit

Weissfeld

Wilson

. Incidence of head and neck squamous cell carcinoma among subjects at high risk of lung cancer: results from the Pittsburgh Lung Screening Study. Cancer 2015 121 9 1431–1435

Moore

Ariyaratne

Badar

. Cancer epidemiology in South Asia - past, present and future. Asian Pac J Cancer Prev 2010 11 Suppl 2 49–66

Joshi

Dutta

Chaturvedi

Nair

Head and neck cancers in developing countries. Rambam Maimonides Med J 2014 5 2 e0009

Negri

Boffetta

Berthiller

. Family history of cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Int J Cancer 2009 124 2 394–401

Arora

Aggarwal

Pathak

Bhandari

Duffoo

Gulati

Molecular genetics of head and neck cancer (Review). Mol Med Rep 2012 6 1 19–22

Kostareli

Holzinger

Hess

New concepts for translational head and neck oncology: lessons from HPV-related oropharyngeal squamous cell carcinomas. Front Oncol 2012 236

Akram

Mirza

Aamir Mirza

Qureshi

Emerging patterns in clinico-pathological spectrum of oral cancers. Pak J Med Sci 2013 29 3 783–787

Larsson

Hedelin

Johansson

Athlin

Eating problems and weight loss for patients with head and neck cancer: a chart review from diagnosis until one year after treatment. Cancer Nurs 2005 28 6 425–435

Singh

Ramamoorthi

Baxi

Jayaraj

Thomas

The risk factors of head and neck cancer and their general patterns in Australia: a descriptive review and update. J Environ Pathol Toxicol Oncol 2014 33 1 45–57

10.

Kumar

Rai

Das

. Alcohol and tobacco increases risk of high risk HPV infection in head and neck cancer patients: study from north-east region of India. PLoS One 2015 10 10 e0140700

11.

Klement

Restricting carbohydrates to fight head and neck cancer-is this realistic?

Cancer Biol Med 2014 11 3 145–161

12.

Bridge

Rashid

Martin

DNA mismatch repair and oxidative DNA damage: implications for cancer biology and treatment. Cancers (Basel) 2014 6 3 1597–1614

13.

Kayani

Khan

Baig

Mahjabeen

Association of RAD 51 135 G/C, 172 G/T and XRCC3 Thr241Met gene polymorphisms with increased risk of head and neck cancer. Asian Pac J Cancer Prev 2014 15 23 10457–10462

14.

Zhao

Wang

Liu

Wei

Correlation between base-excision repair gene polymorphisms and levels of in-vitro BPDE-induced DNA adducts in cultured peripheral blood lymphocytes. PLoS ONE 2012 7 7 e40131

15.

Latimer

Majekwana

Pabón-Padín

Pimpley

Grant

Regulation and disregulation of mammalian nucleotide excision repair: a pathway to nongermline breast carcinogenesis. Photochem Photobiol 2015 91 2 493–500

16.

Shen

Fox

Ahn

Loeb

A rapid assay for measuring nucleotide excision repair by oligonucleotide retrieval. Sci Rep 2014 44894

17.

Zhang

Zhao

Hou

Liu

Lack of association between the XPD Lys751Gln polymorphism and colorectal cancer risk: a meta-analysis. Onco Targets Ther 2014 71255–1260

18.

Lin

Zheng

Association of XPD Lys751Gln polymorphism with head and neck cancer susceptibility: evidence from 11,443 subjects. Diagn Pathol 2014 9 1 15

19.

Visuvanathan

Chong

Yap

Lim

Tan

Lye

Distribution and haplotype associations of XPD Lys751Gln, XRCC1 Arg280His and XRCC1 Arg399Gln polymorphisms with nasopharyngeal carcinoma in the Malaysian population. Asian Pac J Cancer Prev 2014 15 6 2747–2751

20.

Yan

Liang

Light

. XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: a meta-analysis. Tumour Biol 2014 35 3 1907–1915

21.

Spivak

Nucleotide excision repair in humans. DNA Repair (Amst) 2015 Sep 10.

22.

Khlifi

Kallel

Hammami

Hamza-Chaffai

Rebai

DNA repair gene polymorphisms and risk of head and neck cancer in the Tunisian population. J Oral Pathol Med 2014 43 3 217–224

23.

Lin

Zheng

Association of XPD Lys751Gln polymorphism with head and neck cancer susceptibility: evidence from 11,443 subjects. Diagn Pathol 2014 9 1 15

24.

Yin

Guo

Wang

Vogel

The DNA repair gene ERCC2/XPD polymorphism Arg 156Arg (A22541C) and risk of lung cancer in a Chinese population. Cancer Lett 2005 223 2 219–226

25.

Bashir

Sana

Mahjabeen

Kayani

Association of reduced XRCC2 expression with lymph node metastasis in breast cancer tissues. Fam Cancer 2014 13 4 611–617

26.

Petruseva

Evdokimov

Lavrik

Molecular mechanism of global genome nucleotide excision repair. Acta Naturae 2014 6 1 23–34

27.

Schena

Guarrera

Buffoni

. DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients. DNA Repair (Amst) 2012 11 4 374–380

28.

Liu

Yin

Reduced expression of human DNA repair genes in esophageal squamous-cell carcinoma in China. J Toxicol Environ Health A 2007 70 11 956–963

29.

Kumar

Pant

Singh

Khandelwal

Reduced expression of DNA repair genes (XRCC1, XPD, and OGG1) in squamous cell carcinoma of head and neck in North India. Tumour Biol 2012 33 1 111–119

30.

Lovato

Marioni

Manzato

. Elderly patients at higher risk of laryngeal carcinoma recurrence could be identified by a panel of two biomarkers (nm23-H1 and CD105) and pN+ status. Eur Arch Otorhinolaryngol 2015 272 11 3417–3424

31.

Mahjabeen

Chen

Zhou

Kayani

Decreased mRNA expression levels of base excision repair (BER) pathway genes is associated with enhanced Ki-67 expression in HNSCC. Med Oncol 2012 29 5 3620–3625

32.

Mahjabeen

Baig

Sabir

Kayani

Genetic and expressional variations of APEX1 are associated with increased risk of head and neck cancer. Mutagenesis 2013 28 2 213–218

33.

Xiao

Shen

Fang

Downregulation of pancreatic-duodenal homeobox 1 expression in breast cancer patients: a mechanism of proliferation and apoptosis in cancer. Mol Med Rep 2012 6 5 983–988

34.

Wang

Zhang

Jin

Pan

Role of centromere protein H and Ki67 in relapse-free survival of patients after primary surgery for hypopharyngeal cancer. Asian Pac J Cancer Prev 2012 13 3 821–825

35.

Jiang

Cheng

Zhang

The prognostic significance of p63 and Ki-67 expression in myoepithelial carcinoma. Head Neck Oncol 2012 4 1 9

36.

De Petrini

Ritt

Schena

. Head and neck squamous cell carcinoma: role of the human papillomavirus in tumour progression. New Microbiol 2006 29 1 25–33

37.

Sturgis

Zheng

. XPD/ERCC2 polymorphisms and risk of head and neck cancer: a case-control analysis. Carcinogenesis 2000 21 12 2219–2223

38.

Sturgis

Dahlstrom

Spitz

Wei

DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2002 128 9 1084–1088

39.

Rydzanicz

Wierzbicka

Gajęcka

Szyfter

The impact of genetic factors on the incidence of multiple primary tumors (MPT) of the head and neck. Cancer Lett 2005 224 2 263–278

40.

Huang

Olshan

Schwartz

. Selected genetic polymorphisms in MGMT, XRCC1, XPD, and XRCC3 and risk of head and neck cancer: a pooled analysis. Cancer Epidemiol Biomarkers Prev 2005 14 7 1747–1753

41.

Kietthubthew

Sriplung

Ishida

Polymorphism in DNA repair genes and oral squamous cell carcinoma in Thailand. Int J Hyg Environ Health 2006 209 1 21–29

42.

Ramachandran

Ramadas

Hariharan

Rejnish Kumar

Radhakrishna Pillai

Single nucleotide polymorphisms of DNA repair genes XRCC1 and XPD and its molecular mapping in Indian oral cancer. Oral Oncol 2006 42 4 350–362

43.

Matullo

Dunning

Guarrera

. DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis 2006 27 5 997–1007

44.

Bau

Tsai

Huang

. Relationship between polymorphisms of nucleotide excision repair genes and oral cancer risk in Taiwan: evidence for modification of smoking habit. Chin J Physiol 2007 50 6 294–300

45.

Wang

Spitz

Lee

Huang

Lippman

Nucleotide excision repair pathway genes and oral premalignant lesions. Clin Cancer Res 2007 13 12 3753–3758

46.

Yang

Wei

. Genetic polymorphisms of the DNA repair gene and risk of nasopharyngeal carcinoma. DNA Cell Biol 2007 26 7 491–496

47.

Majumder

Sikdar

Ghosh

Roy

Polymorphisms at XPD and XRCC1 DNA repair loci and increased risk of oral leukoplakia and cancer among NAT2 slow acetylators. Int J Cancer 2007 120 10 2148–2156

48.

Liu

. Potentially functional single nucleotide polymorphisms in the core nucleotide excision repair genes and risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 2007 16 8 1633–1638

49.

Harth

Schafer

Abel

. Head and neck squamous-cell cancer and its association with polymorphic enzymes of xenobiotic metabolism and repair. J Toxicol Environ Health A 2008 71 13-14 887–897

50.

Mitra

Singh

Garg

Chaturvedi

Sharma

Rath

Statistically significant association of the single nucleotide polymorphism (SNP) rs13181 (ERCC2) with predisposition to squamous cell carcinomas of the head and neck (SCCHN) and breast cancer in the north Indian population. J Exp Clin Cancer Res 2009 28 1 104

51.

Abbasi

Ramroth

Becher

Dietz

Schmezer

Popanda

Laryngeal cancer risk associated with smoking and alcohol consumption is modified by genetic polymorphisms in ERCC5, ERCC6 and RAD23B but not by polymorphisms in five other nucleotide excision repair genes. Int J Cancer 2009 125 6 1431–1439

52.

Jelonek

Gdowicz-Klosok

Pietrowska

. Association between single-nucleotide polymorphisms of selected genes involved in the response to DNA damage and risk of colon, head and neck, and breast cancers in a Polish population. J Appl Genet 2010 51 3 343–352

53.

Tae

Lee

. XPD polymorphisms and risk of squamous cell carcinoma of the head and neck in a Korean sample. Clin Exp Otorhinolaryngol 2010 3 1 42–47

54.

Mahimkar

Samant

Kannan

Patil

Influence of genetic polymorphisms on frequency of micronucleated buccal epithelial cells in leukoplakia patients. Oral Oncol 2010 46 10 761–766

55.

Gugatschka

Dehchamani

Wascher

Friedrich

Renner

DNA repair gene ERCC2 polymorphisms and risk of squamous cell carcinoma of the head and neck. Exp Mol Pathol 2011 91 1 331–334

56.

Sliwinski

Przybylowska

Markiewicz

. MUTYH Tyr165Cys, OGG1 Ser326Cys and XPD Lys751Gln polymorphisms and head neck cancer susceptibility: a case control study. Mol Biol Rep 2011 38 2 1251–1261

57.

Kumar

Pant

Singh

Khandelwal

Associated risk of XRCC1 and XPD cross talk and life style factors in progression of head and neck cancer in north Indian population. Mut Res 2012 729 1-2 24–34

58.

Yuan

. Genetic polymorphisms in key DNA repair genes and risk of head and neck cancer in a Chinese population. Exp Ther Med 2012 3 4 719–724

59.

Kostrzewska-Poczekaj

Gawęcki

Illmer

. Polymorphisms of DNA repair genes and risk of squamous cell carcinoma of the head and neck in young adults. Eur Arch Otorhinolaryngol 2013 270 1 271–276

60.

Gao

Yang

Laryngeal cancer risk and common single nucleotide polymorphisms in nucleotide excision repair pathway genes ERCC1, ERCC2, ERCC3, ERCC4, ERCC5 and XPA. Gene 2014 542 1 64–68

61.

Cheng

Sturgis

Eicher

Spitz

Wei

Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. Cancer 2002 94 2 393–397

Increased Expression of ERCC2 Gene in Head and Neck Cancer is Associated with Aggressive Tumors: A Systematic Review and Case-Control Study

Abstract

Introduction

Aim

Method

Result

Conclusions

Keywords

Introduction

Materials and methods

Publication Search

Tumor Sample Collection

RNA Extraction and cDNA Synthesis

Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)

Quantitative Polymerase Chain Reaction (qPCR)

Statistical Analysis

Results

Study Characteristics

Expression of ERCC2 measured by RT-PCR

Expression of XPD/ERCC2 measured by qPCR

Expression of Ki-67 measured by qPCR

Correlations between different Clinicopathological Characteristics

Discussion

Footnotes

Acknowledgment

References